Article

Assessment of Health-Related Quality of Life after the Second Cycle of Chemotherapy in Esophageal Cancer Patients: A Prospective Cross-Sectional Study

Vishal Kulkarni1, Kavya Mattikatti2, Manasa Desai2, Darshan Randewadi2, Nida Sirdesai2, Sanatkumar Bharamu Nyamagoud3★, AHM Viswanatha Swamy2★ Corresponding author

  1. 1Department of Medical Oncology, Karnataka Medical College and Research Institute, Hubballi, Karnataka, INDIA.
  2. 2Department of Pharmacy Practice, KLE College of Pharmacy, Hubballi, KLE Academy of Higher Education and Research (Deemed-to-be-University), Belagavi, Karnataka, INDIA.
  3. 3Department of Pharmacy Practice, SDM Trust’s Danigond College of Pharmacy, Terdal, Karnataka, INDIA.

CORRESPONDENCE

Sanatkumar Bharamu Nyamagoud

Department of Pharmacy Practice, SDM Trust’s Danigond College of Pharmacy, Terdal, Karnataka, INDIA.

dr.sanathnyamagoud@gmail.com

Received: 09-04-2026; Revised: 25-06-2026; Accepted: 11-08-2026.

Volume 16, Issue 4 · pp. 1719–1724 · PUBLISHED 2026 · DOI: 10.5530/ijpi.20260176

View on IJPI original site ↗

ABSTRACT

Aim: To evaluate early changes in symptom-specific Health-Related Quality of Life (HRQoL) among Esophageal cancer patients receiving chemotherapy up to the second cycle and to assess demographic and treatment-related differences in early responses. Materials and Methods: A total of 56 patients with histologically confirmed Esophageal cancer were evaluated prospectively before chemotherapy initiation and after the second cycle. HRQoL was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Esophageal Cancer (EORTC QLQ-OES25). Domain scores were linearly transformed to a 0-100 scale according to the EORTC scoring manual, and changes from baseline to the second cycle were analyzed using paired t-tests and Pearson correlation. Results: The majority of patients were aged 45-64 years (57%) and male (66%). Stage III disease was most common (48%), and 77% received palliative chemotherapy. The mean overall symptom-specific HRQoL score improved modestly from 59.75±16.48 at baseline to 61.80±17.18 after the second cycle (p=0.032). Younger patients (25-44 years), females, and those receiving adjuvant therapy showed the greatest improvements. The correlation between baseline and post-cycle scores was strong (r=0.88, p<0.001). The highest symptom burden was noted in pain, odynophagia, and eating restriction domains. Conclusion: Early improvements in symptom-specific HRQoL were observed after two chemotherapy cycles, especially among younger and adjuvant-therapy patients. Routine early-cycle HRQoL monitoring using the EORTC QLQ-OES25 may help assess treatment tolerance and patient adaptation. Larger multicenter studies with longer follow-up are warranted.

KEYWORDS

Open in new tab

REFERENCES

As published

Showing references and in-text citations exactly as published.

    Cite this article

    SELECT FORMAT

    Kulkarni, V., Mattikatti, K., Desai, M., Randewadi, D., Sirdesai, N., Nyamagoud, S. B., & Swamy, A. V. (2026). Assessment of Health-Related Quality of Life after the Second Cycle of Chemotherapy in Esophageal Cancer Patients: A Prospective Cross-Sectional Study. International Journal of Pharmaceutical Investigation, 16(4), 1719–1724. https://doi.org/10.5530/ijpi.20260176